Figure 2.
Overall survival curves. (A) Survival in 133 Mayo Clinic patients with PV stratified by the presence or absence of “adverse” (ASXL1, SRSF2, IDH2) or “other” (TET2, SH2B3, SF3B1, SETBP1, DNMT3A, CSF3R, CEBPA, SUZ12, ZRSR2, KIT, RUNX1, FLT3, CBL, and TP53) DNA sequence variants/mutations. (B) Survival in 215 Italian patients with PV stratified by the presence or absence of adverse (ASXL1, SRSF2, IDH2) variants/mutations. (C) Survival in 183 Mayo Clinic patients with ET stratified by the presence or absence of “adverse” (SH2B3, IDH2, SF3B1, U2AF1, EZH2, TP53) or “other” (TET2, ASXL1, PTP11, SUZ12, ZRSR2, CBL, CEBPA, CSF3R, DNMT3A, SRSF2, FLT3, KIT, NRAS, RUNX1, SETBP1) sequence variants/mutations. (D) Survival in 174 Italian patients with ET stratified by the presence or absence of adverse (SH2B3, IDH2, SF3B1, U2AF1, EZH2, TP53) variants/mutations.

Overall survival curves. (A) Survival in 133 Mayo Clinic patients with PV stratified by the presence or absence of “adverse” (ASXL1, SRSF2, IDH2) or “other” (TET2, SH2B3, SF3B1, SETBP1, DNMT3A, CSF3R, CEBPA, SUZ12, ZRSR2, KIT, RUNX1, FLT3, CBL, and TP53) DNA sequence variants/mutations. (B) Survival in 215 Italian patients with PV stratified by the presence or absence of adverse (ASXL1, SRSF2, IDH2) variants/mutations. (C) Survival in 183 Mayo Clinic patients with ET stratified by the presence or absence of “adverse” (SH2B3, IDH2, SF3B1, U2AF1, EZH2, TP53) or “other” (TET2, ASXL1, PTP11, SUZ12, ZRSR2, CBL, CEBPA, CSF3R, DNMT3A, SRSF2, FLT3, KIT, NRAS, RUNX1, SETBP1) sequence variants/mutations. (D) Survival in 174 Italian patients with ET stratified by the presence or absence of adverse (SH2B3, IDH2, SF3B1, U2AF1, EZH2, TP53) variants/mutations.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal